NR-55616来自SARS相关冠状病毒2的刺突糖蛋白(稳定）,具有C末端组氨酸和Avi标签的A.23.1谱系,来自HEK293细胞(蛋白质）的重组
产品图片
货号/SKU
NR-55616
货号/规格
EA
库存与交货期
3-8周
人民币价格
14000
试剂海关审批
A/B级风险物质只能直接使用人购买并持有实验室有效资质，其它询客服确认
国外采购
支持/部分限制一年内购买数量
厂牌
BEI Resources(ATCC)
产品基础信息
生物安全等级建议分类：美国、1
产品描述信息
NR-55616?? Spike Glycoprotein (Stabilized) from SARS-Related Coronavirus 2, A.23.1 Lineage with C-Terminal Histidine and Avi Tags, Recombinant from HEK293 Cells(Proteins)|SARS-Related Coronavirus 2|Spike Glycoprotein (Stabilized) from SARS-Related Coronavirus 2, A.23.1 Lineage with C-Terminal Histidine and Avi Tags, Recombinant from HEK293 Cells|-20°C or colder|BEI ResourcesAcknowledgment for publications should read “The following reagent was obtained through BEI Resources, NIAID, NIH: Spike Glycoprotein (Stabilized) from SARS-Related Coronavirus 2, A.23.1 Lineage with C-Terminal Histidine and Avi Tags, Recombinant from HEK293 Cells, NR-55616.”|Quantity limit per order for this item is 1. This item can be ordered twice a year. Orders over this limit will be sent to NIAID for approval before shipment.
A recombinant form of the spike (S) glycoprotein from severe acute respiratory syndrome-related coronavirus 2 (SARS-CoV-2), A.23.1 lineage was produced in human embryonic kidney HEK293 cells and purified by immobilized metal affinity chromatography. NR-55616 lacks the signal sequence and contains 1196 residues (ectodomain) of the SARS-CoV-2 S glycoprotein; the recombinant protein was stabilized by substitution at the furin S1/S2 cleavage site (RRAR→GSAS; residues 682 to 685) and KV→PP mutations (residues 986 and 987; wild type numbering), and includes a T4 foldon trimerization domain, HRV3C protease cleavage site and C-terminal octa-histidine tag fused to an AviTag? BirA biotinylation acceptor sequence. NR-55616 includes F157L, V367F, Q613H and P681R mutations in the S glycoprotein as compared to the SARS-CoV-2 reference sequence (GenPept: QHD43416). NR-55616 has a theoretical molecular weight of 139,800 daltons. The crystal structure for trimeric S glycoprotein from SARS-CoV-2 has been solved at 3.46 ? resolution (PDB: 6VSB).
The S glycoprotein mediates viral binding to the host angiotensin converting enzyme 2 (ACE2). This protein forms a trimer, and when bound to a host receptor allows fusion of the viral and cellular membranes. The A.23.1 lineage emerged in mid-2020 in Uganda and includes the E484K and N501Y mutations in the S glycoprotein Receptor Binding Domain (RBD), which substantially compromise vaccine efficacy and antibody treatments.
Each vial contains approximately 100 ?L of NR-55616 in 10 mM HEPES, pH 7, 150 mM NaCl and 2 mM ethylenediamine-tetraacetic acid (EDTA).
Additional information and tools are available at ViPR (Virus Pathogen Resource).
A recombinant form of the spike (S) glycoprotein from severe acute respiratory syndrome-related coronavirus 2 (SARS-CoV-2), A.23.1 lineage was produced in human embryonic kidney HEK293 cells and purified by immobilized metal affinity chromatography. NR-55616 lacks the signal sequence and contains 1196 residues (ectodomain) of the SARS-CoV-2 S glycoprotein; the recombinant protein was stabilized by substitution at the furin S1/S2 cleavage site (RRAR→GSAS; residues 682 to 685) and KV→PP mutations (residues 986 and 987; wild type numbering), and includes a T4 foldon trimerization domain, HRV3C protease cleavage site and C-terminal octa-histidine tag fused to an AviTag? BirA biotinylation acceptor sequence. NR-55616 includes F157L, V367F, Q613H and P681R mutations in the S glycoprotein as compared to the SARS-CoV-2 reference sequence (GenPept: QHD43416). NR-55616 has a theoretical molecular weight of 139,800 daltons. The crystal structure for trimeric S glycoprotein from SARS-CoV-2 has been solved at 3.46 ? resolution (PDB: 6VSB).
The S glycoprotein mediates viral binding to the host angiotensin converting enzyme 2 (ACE2). This protein forms a trimer, and when bound to a host receptor allows fusion of the viral and cellular membranes. The A.23.1 lineage emerged in mid-2020 in Uganda and includes the E484K and N501Y mutations in the S glycoprotein Receptor Binding Domain (RBD), which substantially compromise vaccine efficacy and antibody treatments.
Each vial contains approximately 100 ?L of NR-55616 in 10 mM HEPES, pH 7, 150 mM NaCl and 2 mM ethylenediamine-tetraacetic acid (EDTA).
Additional information and tools are available at ViPR (Virus Pathogen Resource).
主要内容
此项目的每个订单数量限制为1.此商品每年可订购两次.此限制的订单将在发货前发送到NIAID批准.
从严重急性呼吸综合征相关的冠状病毒2（SARS-COV-2）中的穗状花序的重组形式，A.23.1谱系在人胚胎肾HEK293细胞中产生，并通过固定化金属亲和层析纯化. NR-55616缺乏信号序列并含有1196个残基（Ectodomain）的SARS-COV-2S糖蛋白;通过在Furin S1 / S2切割位点（RRAR→GSAS;残基682至685）和KV→PP的替代物稳定重组蛋白质稳定
突变（残留物986和987;野生型编号），包括T4粘合三聚体化结构域，HRV3C蛋白酶切割位点和C末端OctA-组氨酸标签融合到Avitag TM Bira Biotinylation受体序列.与SARS-COV-2参考序列相比/ qhd43416“> qhd43416 ）. NR-55616有一个
理论分子量为139,800道尔顿. SARS-COV-2的三聚糖蛋白的晶体结构已在3.46?分辨率（PDB： 6vsb ）中得到解决.
S糖蛋白介导与宿主血管紧张素转化酶2（ACE2）的病毒结合.该蛋白质形成三聚体，并且当与宿主受体结合时，允许融合病毒和细胞膜. A.23.1谱系在乌干达中2020年代出现，包括S糖蛋白受体结合结构域（RBD）中的E484K和N501Y突变，其基本上损害了疫苗疗效和抗体
治疗.
每个小瓶在10mM HEPES中含有约100μl的NR-55616，pH 7,150mM NaCl和2mm
乙二胺 - 四乙酸（EDTA）.
vipr （病毒病原体资源）提供了附加信息和工具.
厂牌介绍
BEI Resources 由美国国家过敏和传染病研究所 ( NIAID )成立，旨在为研究 A、B 和 C 类优先病原体、新兴传染病病原体、非病原微生物和其他相关微生物材料提供试剂、工具和信息到研究界。BEI Resources 获取、验证和生产科学家进行基础研究和开发改进的诊断测试、疫苗和疗法所需的试剂。通过将这些功能集中在 BEI Resources 中，可以监控科学界对这些材料的访问和使用，并确保试剂的质量控制。
除了为传染病界提供材料外，BEI Resources 还鼓励和支持研究人员和机构的材料存放。使用 BEI Resources存放材料对研究人员和研究社区有许多优势，包括安全存储、社区访问和分发；同时保护存款人的知识产权。只要有需要，BEI 资源库将作为研究人员的资源进行维护。您在 BEI Resources 的存款是一项有助于未来研究的长期投资。
BEI Resources 自 2003 年起由美国典型培养物保藏中心 (ATCC) 根据合同管理。2016 年 5 月， ATCC获得了一份为期七年的继续管理 BEI Resources的合同。合同范围已扩大到更全面的研究目录材料，包括由其他政府支持的研究项目存放的材料，将提供给生物防御和新兴传染病科学界。真菌、寄生虫、载体和其他相关材料已添加到现有的细菌、病毒和毒素试剂中，涵盖 NIAID A、B 和 C 类优先病原体和 NIAID 指定的新发传染病病原体和生物。
品牌标识
可能感兴趣的内容
2022-04-01
2022-04-01
2021-12-21
2024-09-22
2022-04-01
2024-10-20
2021-12-21
2022-03-31
2024-05-19
2022-04-01
2021-12-13
2024-06-25
2022-04-01